Endo rated outperform by RBC

RBC Capital Markets analyst Ken Trbovich gave Endo Pharmaceuticals Holdings Inc. an outperform, above average risk, rating. The company reported revenue of $217 million, beating the analyst's estimate of $213 million but short of Street consensus of $223 million. Lidoderm revenues of $127 million beat RBC's estimate of $122 million. Earnings of $0.33 per share were in-line with expectations while research and development came in about $2 million less than expected. The company did not recognize any Opana revenue in the third quarter and deferred $12.7 million in stocking orders to future periods. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up 7 cents, or 0.24%, at $29.48. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.